Bicara's Ficerafusp Alfa Doubles 3-Year Overall Survival in Head & Neck Cancer
BCAX has more than doubled off its 52-week low of $7.8.
Summary
Bicara Therapeutics announced compelling three-year follow-up data from its Phase 1/1b study of ficerafusp alfa in combination with pembrolizumab for recurrent/metastatic HPV-negative head and neck squamous cell carcinoma. The 1500mg dose showed an estimated 31% overall survival at three years, approximately doubling the survival rate observed with standard of care. This strong long-term efficacy data reinforces the potential of ficerafusp alfa, which is currently in the pivotal Phase 3 FORTIFI-HN01 study, initiated in March 2026. Doubling overall survival in this difficult-to-treat cancer is a significant clinical achievement that could substantially de-risk the ongoing Phase 3 trial and enhance the drug's market potential. The company also recently reported a strong cash position extending into the first half of 2029, providing ample funding for its clinical programs. Investors will be watching for further updates from the ongoing Phase 3 study.
At the time of this announcement, BCAX was trading at $20.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $7.80 to $24.25. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.